Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xoft grabs $25m for Axxent

This article was originally published in Clinica

Executive Summary

Sunnyvale, California-based brachytherapy specialist Xoft has raised $25m from a series E preferred stock financing led by new investor Chicago Growth Partners. Xoft said it will use the funds to complete post-market studies of its Axxent electronic brachytherapy system for breast cancer and expand commercialisation activities for the product. The new capital will also go towards advancing two new applications of the technologies: endometrial and rectal cancers. Axxent, which was cleared by the FDA in 2006, delivers localised, non-radioactive, isotope-free radiation to cancer sites.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041612

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel